May 7, 2024 – Page 14 – Goldea Capital

Integer to Showcase Strategic Investments to Support Customers’ Growth and Innovation at Heart Rhythm 2024

Written by Customer Service on May 7, 2024. Posted in Public Companies.

PLANO, Texas, May 07, 2024 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will join medtech industry leaders around the world in exhibiting at Heart Rhythm 2024, a Heart Rhythm Society (HRS) educational event and exhibition in Boston from May 16 – 19, 2024. HRS attendees are invited to visit Integer at booth #753 to learn more about the company’s comprehensive end-to-end solutions, designed to help customers accelerate time to market, strengthen innovation, simplify supply chain and confidently scale production across a globally competitive network of locations. Some examples include market-leading battery technology, finished leads and implantable pulse generators (IPG) for cardiac applications. Integer is a leading manufacturer...

Dayforce Releases Dayforce Partner Exchange

Written by Customer Service on May 7, 2024. Posted in Public Companies.

An open and connected marketplace to help Dayforce customers accelerate HR innovation and unlock more value MINNEAPOLIS and TORONTO, May 07, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced the availability of Dayforce Partner Exchange, a curated ecosystem of software and services partners that implement and extend Dayforce solutions. Dayforce customers are now able to access fully vetted system integrators and technology providers within the Dayforce platform, helping to accelerate business goals and drive value. “Today’s organizations are facing a complexity crisis driven by a changing labor market, regulatory intricacies, and the ever-pressing need to meet market demand,” said Josh Valdez, Senior Vice President, Product,...

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Written by Customer Service on May 7, 2024. Posted in Public Companies.

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024. The call will include a discussion of first quarter 2024 financial results and a corporate update. The live call can be accessed by dialing USA / International Toll +1 .646.968.2525USA – Toll-Free +1.888.596.4144 The live and archived webcast of the call will also be available on the BioStem Technologies website under the Investors...

Speedemissions, Inc. Announces Student Winners of its Inaugural $100,000 “Project Planet Young Entrepreneur” Competition

Written by Customer Service on May 7, 2024. Posted in Public Companies.

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) — Speedemissions, Inc. (OTC Markets Expert Market: SPMI) (the “Company”), a retail brand vehicle testing and safety inspections company that has helped reduce auto emissions for over 20 years, with nineteen operating stores in Atlanta and St. Louis markets, is pleased to announce the winners of its Project Planet Young Entrepreneur competition. On May 2nd, a committee comprised of business and environmental professionals selected two standout student contributors for recognition: Danielle Hanson proposed an innovative storage container utilizing a solar-powered filtration system for processing rain or ground-sourced water. Shuham Madhavi submitted a bio-brick technology converting CO2 into coral-restoring nutrients to help regenerate reef ecosystems and combat climate change. Speedemissions...

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: Revenue of $1.9 million, a 2% increase over the prior-year period. Consumables sales, representing 82% of total revenue, grew 11% year-over-year. Pediatric revenue growth of 40% year over year led by a 54% increase in consumable sales. Gross margin of 64.1%, compared to 58.4% in the prior year period. Received FDA clearance for an additional dual lumen extended length catheter. Launched Aquadex® ultrafiltration therapy for heart failure patients as a part of Nuwellis’ pivotal REVERSE-HF clinical study at Henry Ford Health. Company anticipates significant expense reductions...

Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or secondary efficacy endpoints The Company implemented cost savings initiatives, including suspension of all mavodelpar development activities and a total workforce reduction of approximately 90% The Company retained an independent financial advisor to initiate a formal process to evaluate potential strategic alternatives Financial...

First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted EBITDA of $28.6 million9 system-wide restaurants opened across 8 states BRADENTON, Fla., May 07, 2024 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended March 31, 2024 (“Q1 2024”). “First Watch posted another solid quarter with positive same restaurant sales*, traffic trends that improved sequentially through the quarter and year-over-year adjusted EBITDA growth,” said Chris Tomasso, First Watch CEO and President. “We continue to focus on delivering...

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 billion in milestones and royalties under license agreement – – Initiated dosing in a first-in-human Phase 1 clinical trial with ARV-102, the first oral PROTAC® degrader in clinical development to treat neurodegenerative diseases – NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer’s disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multiple anticipated value-creating catalysts WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the first quarter ended...

Harvard Bioscience Announces First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of 60%. After quarter end, we announced a cost reduction initiative to improve our operating cost structure and support our ongoing investments in growth.” Green continued, “Looking ahead, we are excited by our growth strategy and new product commercializations. Together with the new round of Chinese stimulus targeting...

Day: May 7, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice